No evidence of anti-competitive behaviour in pharmaceutical, building material sectors — MyCC

KUALA LUMPUR: The Malaysia Competition Commission (MyCC) said there was no conclusive evidence of anti- competitive behaviour between industry players in the pharmaceutical and building material sectors in Malaysia based on its two market review reports.

The findings of the two market reviews — ‘ Market Review on Pharmaceutical Sector’ and ‘ Market Review on Building Materials in the Construction Industry’ — were presented at the MYCC event on “Strengthening Competition through Market Review”, here, yesterday.

Commission member, Prof Dr Saadiah Mohamad said MyCC was able to do its assessment despite the scarcity of ready data within the supply chains and difficulty in collecting the primary data for information due to low cooperation from the industry players.

“MyCC will continue to monitor the progress and competition processes in both sectors. The MyCC is committed to safeguarding the process of competition where it encourages efficiency, innovation and entrepreneurship.

“This commitment promotes competitive prices, improvement in the quality of products and services, and wider choices for consumers, thus, it is for the benefit of the whole nation,” she added.

The review by the MyCC on any market was in accordance with Section 11(1) of the Competition Act 2010.

The two reports were finalised after public consultation sessions held in 2017 and were first published on the MyCC’s website on Jan 8, 2018. — Bernama